Acute Porphyria Drugs

C03AB01 - Bendroflumethiazide and Potassium

Probably not porphyrinogenic
PNP

Mono.Rationale
Sulfonamide type of drug. Clinical experience points to non-porphyrinogenicity. There are references that warn against the drug. Combined with potassium chloride.
Mono.TherapeuticCharacteristics
Thiazide diuretic and antihypertensive.
Mono.MetabolismAndPharmacokinetics
The major part of the drug is eliminated via non-renal mechanisms, only 30 % excreted in unchanged form in urine. More specific data on metabolism are lacking. No observations of CYP interaction. Bendroflumethiazide is a sulfonamide type drug, a drug group often incriminated in acute porphyric attacks. Combined with potassium chloride.
Mono.PersonalCommunication
Thunell, patient report (n=1): tolerated. Andersson, patient report (n=11): tolerated.
Mono.PublishedExperience
None.
Mono.IpnetDrugReports
Uneventful use reported in 1 patient with acute porphyria.
Mono.SimilarDrugs
Mono.ExploreAlternatives C03A / C03AB or Mono.GoBack.
Mono.References
# Citation details PubMed ID
1. Pharmacokinetics of bendroflumethiazide.
Beermann B, Groschinsky-Grind M, Lindstrom B. Clin Pharmacol Ther. 1977 Oct;22(4):385-8. PMID: 902450
902450
Mono.Tradenames

Centyl K · Neo-Naclex-K Bendroza · Centyl Kaliumklorid Centyl · Salures-k Bendroza · Centyl kaliumklorid Centyl K Centyl kaliumklorid
In cooperation with Ipnet
© Napos 2026
An unhandled error has occurred. Reload 🗙